Laurion Capital Management’s AstraZeneca AZN Stock Holding History

Laurion Capital Management’s Portfolio AZN Stock Details AZN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.87M	Hold	9,500	–	–	0.08%	219
2025 Q4	$1.75M	Hold	9,500	–	–	0.07%	108
2025 Q3	$1.46M	Buy	+9,500	New	+$1.44M	0.03%	174
2024 Q3	–	Sell	-38,940	Closed	-$6.07M	–	311
2024 Q2	$6.07M	Buy	+38,940	New	+$5.86M	0.07%	150
2022 Q4	–	Sell	-168,493	Closed	-$18.5M	–	418
2022 Q3	$18.5M	Buy	168,493 +150,880	+857%	+$19.1M	0.11%	144
2022 Q2	$2.33M	Buy	+17,613	New	+$2.31M	0.04%	220
2021 Q4	–	Sell	-6,000	Closed	-$721K	–	557
2021 Q3	$721K	Buy	+6,000	New	+$698K	﹤0.01%	540
2019 Q3	–	Sell	-3,650	Closed	-$301K	–	1011
2019 Q2	$301K	Buy	+3,650	New	+$286K	﹤0.01%	778
2018 Q4	–	Sell	-2,850	Closed	-$226K	–	1103
2018 Q3	$226K	Buy	+2,850	New	+$216K	﹤0.01%	1009
2017 Q3	–	Sell	-351,200	Closed	-$23.9M	–	1547
2017 Q2	$23.9M	Buy	+351,200	New	+$22.9M	0.13%	147

Other funds holding AZN

Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

VAM

Vanguard Asset Management London, Ec4n 8af $117B AUM

Laurion Capital Management's AZN Position: Q1 2026 in Review

Laurion Capital Management held its AstraZeneca (AZN) position steady in Q1 2026 at 9,500 shares worth $1.87M. The position accounts for 0.08% of the portfolio, ranked #219.

Laurion Capital Management first reported a position in AZN in Q2 2017 and has held it in 10 quarters since. The position peaked at $23.9M in Q2 2017. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

Laurion Capital Management held 9,500 shares of AstraZeneca worth $1.87M as of Q1 2026.
Laurion Capital Management left its AstraZeneca share count unchanged in Q1 2026.
AstraZeneca made up 0.08% of Laurion Capital Management's portfolio in Q1 2026, its #219 holding.
Laurion Capital Management first reported a position in AstraZeneca in Q2 2017 and has held it in 10 quarters since.
Laurion Capital Management's AstraZeneca position peaked at $23.9M in Q2 2017.
1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Laurion Capital Management's 13F filing for Q1 2026, filed 14 May 2026.